Proteomic differences among patients with heart failure taking furosemide or torsemide.

ABSTRACT:

Background

Loop diuretics are commonly used for patients with heart failure (HF) but it remains unknown if one loop diuretic is clinically superior.

Hypothesis

Biomarkers and proteomics provide insight to how different loop diuretics may differentially affect outcomes.

Methods

Blood and urine were collected from outpatients with HF who were taking torsemide or furosemide for >30 days. Differences were assessed in cardiac, renal, and inflammatory biomarkers and soluble protein panels using the Olink Cardiovascular III and inflammation panels.

Results

Of 78 subjects, 55 (71%) were treated with furosemide and 23 (29%) with torsemide, and 25 provided a urine sample (15 treated with furosemide, 10 with torsemide). Patients taking torsemide were older (68 vs 64 years

SUBMITTER: Cooper LB 

PROVIDER: S-EPMC8922525 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature